This trial is evaluating whether iNO will improve 5 primary outcomes and 7 secondary outcomes in patients with Hypertension. Measurement will happen over the course of During a single right heart catheterization procedure.
This trial requires 17 total participants across 2 different treatment groups
This trial involves 2 different treatments. INO is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.